Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Friday, November 6, 2026

Back to the front page

Post Q3 EVC Update

EVC's Q3 update cites $30 million for a single station, a broadcast-business sale and stronger positioning for 2027.

EVC $832M
Nat Stewart - Stock Picking Newsletter 21 clicks

From X

@majgeoinvesting 1 click

Maj Soueidan on X

Excerpts from our morning email on $BRM.V and Hammond Manufacturing ( $HMMAF) BRM was clearly the best company I met at the @PlanetMicroCap Toronto conference last week. Whenever anyone asked me the question of who I liked the best at the conference, one stock came out of my mouth. It was BRM. Today’s record quarter supports this opinion and explains why we recently added it to our model portfolio platform. Biorem continues to display operating leverage, with revenue up 48% while EPS more than doubled… The Hammond Manufacturing story is just another example of how one of the best Multi Bagger factors to monitor is companies going through capacity expansions. This is especially true for those that are considered to be value traps trading at deep value levels because investors have lost faith in management’s commitment to shareholder-friendly capital allocation initiatives. We saw that happen with $MUEL before it rose 10x, and now we’re seeing it happen with Hammond Manufacturing…
@kevin__mak 1 click

Kevin Mak on X

$CMPS No change to my position here, still ~10% of my book. Assuming reports are right, Usona's filing was sooner than I expected, and the timing is probably because they filed without durability data. CMPS has announced on earnings that they will file within the next 2 weeks. I think both have a very high chance of getting approved, and given they both have CNPV's, the approvals should be within 2 weeks of each other (FDA may just do both on the same day?). Usona filing and getting approved was always likely, so the reaction on Monday is odd. Even though they filed earlier than I expected, it doesn't change the long term competitive structure of the market. Sell side notes share my opinion that Usona still has many issues to resolve to be competitive- and there's room in the market for them to coexist. Excited to see the approvals on the very near time horizon and we can start seeing the commercialization steps take form. My guess is stock price reactions are just reflecting how jittery the markets are these days. Disclosure: Creek Drive and its affiliated funds holds a long position in CMPS. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information.
@StableBread

Fajasy on X

From $3.83/share, you’re risking a $1.62 loss (-42.3%) on TOYO Co., Ltd $TOYO in my bear case for a $10.90 gain (+284.6%) in my bull case. I apply 2.0-4.0x EBITDA, well below First Solar $FSLR’s 6.7x, for the trade and governance risks. At the 3.0x midpoint, today’s $137.2M EV implies $TOYO earns just $45.7M/year, 29.2% of its TTM figure. How much of the $156.4M of TTM EBITDA lasts depends on Commerce, U.S. customs (CBP), and $TOYO’s Section 232 term sheet (its request for relief from the new 15% tariff on imported cells). Each case values $TOYO at the end of 2027 on that year’s EBITDA, since 2027 is the first full year under the new tariff and Commerce’s final determination is due ~May 13, 2027. I leave out the 45X tax credits, which $TOYO also leaves out of its forecasts, and the HJT cell plant it plans in Texas, which won’t produce before 2028. Each case adds today’s $26.4M of net cash to 2027 EBITDA times the multiple and divides by 42.7M shares. Bear Case ($2.21, -42.3%) The bear case assumes Commerce’s preliminary determination (its first ruling, due ~December 14) covers Ethiopian cells without the certification path $TOYO asked for, CBP keeps detaining shipments, and Commerce doesn’t approve $TOYO’s Section 232 term sheet. That means Ethiopia’s cells stop reaching U.S. buyers in 2027, which implies 2027 EBITDA of $34.0M, what $TOYO earned in Q2 2026 alone. I apply a 2.0x multiple, under a third of First Solar’s 6.7x, for a value of $2.21/share. Base Case ($6.38, +66.6%) The base case assumes Commerce lets cells made with non-Chinese wafers through by its May 2027 final determination, but CBP’s reviews and the inquiry keep Ethiopia’s U.S. sales below their H1 2026 pace until then. That implies 2027 EBITDA of $82.1M, the same as H1 2026 alone, or 52.5% of the TTM figure. I apply a 3.0x multiple, under half of First Solar’s 6.7x, for a value of $6.38/share. Bull Case ($14.73, +284.6%) The bull case assumes Commerce’s preliminary determination clears cells made with non-Chinese wafers, CBP releases $TOYO’s shipments, and Commerce approves its Section 232 term sheet, so Ethiopia’s cells reach U.S. buyers at the H2 2025-H1 2026 pace again. That implies 2027 EBITDA of $156.4M, equal to the TTM figure. I apply a 4.0x multiple, still well below First Solar’s 6.7x, for a value of $14.73/share after the warrants are exercised.
@DOMOCAPITAL 2 clicks

DOMO Capital Management, LLC on X

For those that missed the Gabelli conference yesterday, the $MNRO CFO had this to say when asked about why they went forward with the Ares financing (TLDR: They are selling the company soon): "We think that Ares is a great partner for us. It provides us a lot of flexibility to operate our business, both from a covenant standpoint, but also doing it with a partner who has experience in the auto aftermarket, and also provides a very sophisticated and tailored private credit solution for us. We had plenty of options as we looked to refinance the credit facility, including our more traditional bank lenders and various different private lenders, but ultimately Ares provided us with the best solution for what we felt were our needs. And our needs really were focused on creating a stable financing backdrop for us over our planning horizon, enabling us to not only execute our growth strategy, but providing flexibility for us to explore a wide range of the alternatives that we're currently evaluating. So we think that this credit facility accomplishes all of those things."

Investor Letters

All letters

Entravision Q3 Update

Entravision’s Q3 ad-tech revenue reached $177.2 million, up 133% year over year, while total revenue rose 88% to $226.3 million and diluted…

EVC $832M
The Value Road 4 clicks

Axon 3Q26 Business Update

Axon cut full-year guidance after delayed federal Dedrone contracts slowed 3Q revenue growth to 28%, while software and services grew 43%.

AXON $31B
Speedwell Memos 2 clicks

GREAT DEC-TECTIVE WORK

Diversified Energy reported $255.6 million of “true” nine-month free cash flow, while its $1.8 billion Birch acquisition would shift…

DEC $900M
The Oak Bloke 2 clicks
AAP · long

Advance Auto Parts INC

Advance Auto Parts, AAP, is presented as a long idea following prior write-ups at $48.81 per share in January 2025.

AAP $2.9B
Value Investors Club 1 click

Trading Post November 5, 2026

MercadoLibre’s logistics expansion cut margins by 60 basis points, while Mercado Pago grew credit 62% with 7% NPLs.

MELI $77B
Cassandra Unchained 2 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 74 of 276

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.